Flo vs Hims & Hers

Vienna Startup Ovulyx Launches Couples-Focused Cycle Tracking App

Stefan Renzler, a Vienna-based developer, has launched Ovulyx, a cycle tracking app designed for couples, allowing both partners to view cycle phases and share an experience log to discover what helps during each phase. Users can track mood, energy, symptoms, and bleeding, with predictions for period, PMS, and fertile window. Partners connect via an invitation code and see a dedicated view with supportive actions. The app also supports trying for a baby and menopause, and allows import from Flo and MyNFP. Available on iOS, Android, and web in 29 languages across 152 countries, it offers a 30-day free trial, with Premium at €4.99 monthly or €49.99 yearly. Prioritizing privacy, data is stored in Western Europe under GDPR, and the app does not sell data or use health data for advertising. Ovulyx competes with Flo for Partners and Clue Connect.

• Ovulyx is a cycle tracking app for couples, launched by Vienna-based developer Stefan Renzler.
• The app is available on iOS, Android, and web in 29 languages across 152 countries.
• Premium costs €4.99 per month or €49.99 per year after a 30-day free trial, including one partner connection.

CIPA Private Right of Action Kept, Shifting Privacy to Research

California's legislature passed a compromise version of SB-690, maintaining most of the private right of action provisions of the California Invasion of Privacy Act (CIPA). This means that juries, rather than regulators, will set privacy standards in the state, as individuals can sue companies for online tracking practices. With over 4,000 CIPA lawsuits filed, mostly against legitimate businesses, the shift emphasizes the need for companies to align data practices with consumer (and juror) expectations. The author argues that privacy compliance should now be research-driven, focusing on customer attitudes, rather than purely legal compliance. This could lead to a competitive advantage for customer-centric businesses over Big Tech, which may face greater legal exposure.

• California passed a compromise version of SB-690, preserving most of the private right of action under CIPA.
• More than 4,000 CIPA lawsuits have been filed, mostly against legitimate businesses.
• A jury verdict against Meta involved data collection from the Flo menstrual tracking app.

Flo Health Appoints Rina Hahn as Chief Marketing Officer

Flo Health has appointed Rina Hahn as Chief Marketing Officer, announced August 26, 2026.

Hims & Hers expands GLP-1 benefits with Tonal, Grüns, Viome, Medjet

Hims & Hers announced an expansion of its Hims & Hers Benefits program, adding four new brand partners: Tonal, Grüns, Viome, and Medjet. The program, launched in March, offers exclusive savings on health-related products and services to GLP-1 subscribers. It has grown from two to 14 brand partners. The company states it passes 100% of negotiated benefits to subscribers, not profiting from partnerships. Benefits include $1,000 off Tonal 2, $30 off Grüns first order, etc. The expansion aims to holistically support GLP-1 weight loss journeys, focusing on muscle maintenance and sustainable habits. Hims & Hers reported 13% YoY subscriber growth in Q3 2026, reaching 2.79 million. The program is part of a trend of platforms adding third-party perks for retention. Executive quotes highlight the value of integrated health support and customer acquisition for brand partners.

• Hims & Hers expanded its Benefits program to include Tonal, Grüns, Viome, and Medjet, bringing total brand partners to 14.
• Benefits include $1,000 off Tonal 2 and $30 off first Grüns order.
• Hims & Hers reported 2.79 million subscribers in Q3 2026, a 13% year-over-year increase.

8-K Financial Filing Analysis for Hims & Hers (2026-10-07)

Hims & Hers Health, Inc. announced the appointment of Jonathan M. Franklin as Chief Accounting Officer and Principal Accounting Officer, effective October 9, 2026. Mr. Franklin succeeds Irene Becklund, who previously resigned but will remain with the company in an advisory capacity through July 10, 2027, ensuring an orderly transition. Prior to joining Hims & Hers, Franklin served as Vice President, Corporate Controller at Rivian Automotive and spent over 15 years in public accounting at PwC. His compensation package includes an annual base salary of $425,000, a $150,000 signing bonus, an annual target bonus of 50%, and an initial grant of $3,000,000 in restricted stock units (RSUs) vesting over four years.

• Jonathan M. Franklin appointed Chief Accounting Officer and Principal Accounting Officer effective October 9, 2026, succeeding Irene Becklund.
• Compensation includes an annual base salary of $425,000, a $150,000 signing bonus, a 50% target discretionary bonus, and $3,000,000 in equity awards (RSUs) vesting over 4 years.
• Outgoing Principal Accounting Officer Irene Becklund will serve under an advisory agreement through July 10, 2027.

Hims & Hers Securities Class Action Deadline Nov 2, 2026

Robbins Geller Rudman & Dowd LLP has announced a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), alleging violations of the Securities Exchange Act. The lawsuit, captioned Velanki v. Hims & Hers Health, Inc., is pending in the Northern District of California. It claims that the company made false statements and failed to disclose that it shared consumers' sensitive health information with third-party advertising platforms like Meta and Snap, and that it misled consumers about billing practices. Following an FTC lawsuit filed on July 29, 2026, the company's stock dropped nearly 15%. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026, to seek lead plaintiff appointment under the Private Securities Litigation Reform Act.

• FTC filed a lawsuit against Hims & Hers on July 29, 2026, alleging sharing of sensitive health data with advertising platforms like Meta and Snap, and misleading billing.
• Hims & Hers stock declined nearly 15% following the FTC announcement.
• Robbins Geller Rudman & Dowd LLP filed a class action lawsuit (Velanki v. Hims & Hers Health, Inc.) in the Northern District of California.